Key result
In hospice patients with non-lung cancers, a natural logarithm-transformed high-frequency power (lnHFP) value below 2 at admission was associated with a higher risk of survival of 7 days or less.
Why the study?
Does heart rate variability predict 7-day survival in hospice patients with advanced non-lung cancers?
Cohort (n=138)
No
Does heart rate variability predict 7-day survival in hospice patients with advanced non-lung cancers?
In hospice patients with advanced non-lung cancers, reduced high-frequency heart rate variability (lnHFP < 2) is a significant predictor of mortality within 7 days.
Answers are grounded in this paper and cite their sources.
May refine short-term prognostication in non-lung cancer hospice patients; leaves open prospective validation before clinical adoption.
BACKGROUND: A simple and accurate survival prediction tool can facilitate decision making processes for hospice patients with advanced cancers. The objectives of this study were to explore the association of cardiac autonomic functions and survival in patients with advanced cancer and to evaluate the prognostic value of heart rate variability (HRV) in 7-day survival prediction. METHODS: A prospective study was conducted on 138 patients with advanced cancer recruited from the hospice ward of a regional hospital in southern Taiwan. Information on functional status and symptom burden of the patients was recorded. Frequency-domain HRV was obtained for the evaluation of cardiac autonomic functions at admission. The end point of the study was defined as the survival status at day 7 after admission to the hospice ward. Multivariate logistic regression analyses were performed to evaluate the independent associations between HRV indices and survival of 7 days or less. RESULTS: The median survival time of the patients was 20 days (95% CI, 17-28 days). Results from the multivariate logistic regression analysis indicated that the natural logarithm-transformed high-frequency power (lnHFP) of a value less than 2 (OR = 3.8, p = 0.008) and ECOG performance status of 3 or 4 (OR = 3.4, p = 0.023) were significantly associated with a higher risk of survival of 7 days or less. Receiver operating characteristic (ROC) curve analysis revealed that the area under the curve was 0.71 (95% CI, 0.61-0.81). CONCLUSIONS: In hospice patients with non-lung cancers, an lnHPF value below 2 at hospice admission was significantly associated with survival of 7 days or less. HRV might be used as a non-invasive and objective tool to facilitate medical decision making by improving the accuracy in survival prediction.
No takes yet. Share an insight, caveat, or question.
Chiang et al. (2013) conducted a cohort in Advanced non-lung cancer (n=138). Natural logarithm-transformed high-frequency power (lnHFP) < 2 vs. lnHFP ≥ 2 was evaluated on Survival of 7 days or less (OR 3.80, 95% CI 1.49-11.12, p=0.008). In hospice patients with non-lung cancers, a natural logarithm-transformed high-frequency power (lnHFP) value below 2 at admission was associated with a higher risk of survival of 7 days or less.
Synapse has enriched 10 related papers. Consider them for comparative context: